Cargando…

Epidemiology of Asymptomatic Pre-heart Failure: a Systematic Review

PURPOSE OF REVIEW: To quantify the prevalence of asymptomatic pre-heart failure (pre-HF), progression to more severe stages, and associated mortality. RECENT FINDINGS: A systematic review was conducted between 01 January 2010 and 12 March 2020 (PROSPERO: CRD42020176141). Data of interest included pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergamasco, Aurore, Luyet-Déruaz, Anouk, Gollop, Nicholas D., Moride, Yola, Qiao, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177493/
https://www.ncbi.nlm.nih.gov/pubmed/35355204
http://dx.doi.org/10.1007/s11897-022-00542-5
Descripción
Sumario:PURPOSE OF REVIEW: To quantify the prevalence of asymptomatic pre-heart failure (pre-HF), progression to more severe stages, and associated mortality. RECENT FINDINGS: A systematic review was conducted between 01 January 2010 and 12 March 2020 (PROSPERO: CRD42020176141). Data of interest included prevalence, disease progression, and mortality rates. In total, 1030 sources were identified, of which, 12 reported on pre-HF (using the ACC/AHA definition for stage B HF) and were eligible. Prevalence estimates of pre-HF ranged from 11 to 42.7% (10 sources) with higher estimates found in the elderly, in patients with hypertension, and in men. Three studies reported on disease progression with follow-up ranging from 13 months to 7 years. The incidence of symptomatic HF (HF/advanced HF) ranged from 0.63 to 9.8%, and all-cause mortality from 1.6 to 5.4%. SUMMARY: Further research is required to investigate whether early detection and intervention can slow or stop the progression from asymptomatic to symptomatic HF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11897-022-00542-5.